Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-Gastric 02: first-line sonesitatug vedotin + capecitabine with or without rilvegostomig in CLDN18.2-positive, HER2-negative advanced gastric/GEJ/esophageal adenocarcinoma
CTR20254901Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sonesitatug vedotin, rilvegostomig, capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by AstraZeneca. Started Mar 2026; status: active.
02
Drugs
sonesitatug vedotinrilvegostomigcapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20254901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254901.